Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Gia Nemsadze, Richard D. Baird, Yeon Hee Park, Peter S. Hall, Timothy Perren, Robert C. Stein, Laszlo Mangel, Jean-Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortes, Andrew Foxley, Elza C. de Bruin, Robert McEwen, Daniel StetsonBrian Dougherty, Shah-Jalal Sarker, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas C. Turner

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science